These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 11120976

  • 21. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007.
    Guembe M, Cercenado E, Alcalá L, Marín M, Insa R, Bouza E.
    Rev Esp Quimioter; 2008 Sep; 21(3):166-73. PubMed ID: 18792817
    [Abstract] [Full Text] [Related]

  • 22. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon.
    Piéboji JG, Koulla-Shiro S, Ngassam P, Adiogo D, Njine T, Ndumbe P.
    Int J Infect Dis; 2004 May; 8(3):147-54. PubMed ID: 15109589
    [Abstract] [Full Text] [Related]

  • 23. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.
    Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II.
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):215-8. PubMed ID: 15766609
    [Abstract] [Full Text] [Related]

  • 24. A comparison of the antimicrobial resistance patterns of gram-negative bacilli isolated from community-private and university-affiliated hospitals from Puerto Rico.
    Vázquez GJ, Robledo IE, Arroyo A, Nadal E, Rodríguez R, Bermúdez M, Colón M.
    P R Health Sci J; 2003 Sep; 22(3):265-71. PubMed ID: 14619453
    [Abstract] [Full Text] [Related]

  • 25. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS, Frei CR.
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [Abstract] [Full Text] [Related]

  • 26. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
    Vay CA, Almuzara MN, Rodríguez CH, Pugliese ML, Lorenzo Barba F, Mattera JC, Famiglietti AM.
    Rev Argent Microbiol; 2005 Nov; 37(1):34-45. PubMed ID: 15991478
    [Abstract] [Full Text] [Related]

  • 27. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P, Bulik CC, Kuti JL, Nicolau DP.
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [Abstract] [Full Text] [Related]

  • 28. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [Abstract] [Full Text] [Related]

  • 29. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 30. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
    Tantisiriwat W, Linasmita P.
    J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
    [Abstract] [Full Text] [Related]

  • 31. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN, Kirby JT, Rhomberg PR.
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [Abstract] [Full Text] [Related]

  • 32. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
    Lee K, Lee HS, Jang SJ, Park AJ, Lee MH, Song WK, Chong Y, Members of Korean Nationwide Surveillance of Antimicrobial Resistance Group.
    J Korean Med Sci; 2001 Jun; 16(3):262-70. PubMed ID: 11447969
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT, Blondeau JM.
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [Abstract] [Full Text] [Related]

  • 34. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 35. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS, Lee SC, Lee N, See LC, Tsai MH, Shieh WB.
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [Abstract] [Full Text] [Related]

  • 36. Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002.
    Wang H, Chen M, China Nosocomial Pathogens Resistance Surveillance Study Group.
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):201-8. PubMed ID: 15766607
    [Abstract] [Full Text] [Related]

  • 37. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).
    Mataseje LF, Bryce E, Roscoe D, Boyd DA, Embree J, Gravel D, Katz K, Kibsey P, Kuhn M, Mounchili A, Simor A, Taylor G, Thomas E, Turgeon N, Mulvey MR, Canadian Nosocomial Infection Surveillance Program.
    J Antimicrob Chemother; 2012 Jun; 67(6):1359-67. PubMed ID: 22398651
    [Abstract] [Full Text] [Related]

  • 38. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

  • 39. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK, Farrell DJ, Sader HS, Jones RN.
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [Abstract] [Full Text] [Related]

  • 40. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT, Farinelli S, Iegri F, Iona E, De Simone C.
    Drugs Exp Clin Res; 1998 Jun; 24(3):139-51. PubMed ID: 9825230
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.